Lung Cancer
Protocol Title: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009)
- Details
ClinicalTrials.gov ID:
NCT06623422
Diagnosis Type:
NA
USOR Number:
- Address
,
P: